CEO of TechBio Platform Company Recruited by Occam Global
In October 2024, Occam recruited Thomas McCauley, PhD, as President and CEO of Neptune Bio, a NYC-based TechBio platform company backed by Lux Capital and KdT Ventures.
Tom joins Neptune from Omega Therapeutics, a Flagship incubated epigenetics platform company, where he has served as Chief Scientific Officer (CSO) from the company's infancy through crossover and a public offering.
Previously, Tom served as CSO of Macrolide Pharma and Translate Bio (acquired by Sanofi for $3.2B). He began his industrial career at Shire.
Tom received a BS and MEng in Applied and Engineering Physics from Cornell and his PhD in Condensed Matter and Materials Physics from the University of Alabama.
About Neptune Bio
Neptune Bio is dedicated to discovering combinatorial cures by identifying the distinct conditions that trigger cellular changes. Their platform integrates groundbreaking biological data with advanced artificial intelligence (AI) to model complex gene synergies, paving the way for the development of new combinatorial therapies.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.